HOVON 150 / AMLSG 29-18 (#793)
Laufzeit: 01.01.2021 - 31.12.2040
Laufzeit: 01.01.2021 - 31.12.2040
A phase 3, multicenter, double-blind, randomized, placebo-controlled study of AG-120 or AG-221 in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, eligible for intensive chemotherapy